Ciaramella Giuseppe

BEAM President Ciaramella sells 35,000 shares ($1.1M) at $32.00; stock now $28.92, down 18.3% from 52-week high

Ciaramella Giuseppe, President of Beam Therapeutics, sold 35,000 shares (35.0K shares) at $32.00 on 2026-02-24, reducing his stake by 15.5% to 190,216 shares (190.2K shares). The sale occurred near the stock's 52-week high of $35.41; the stock has since fallen to $28.92, now 18.3% below that peak. At his cross-ticker track record level, his prior 4 open-market sells showed a 75.00% well-timed rate with an average 90-day return of -22.3%, while at this specific ticker, 3 of 4 prior BEAM sales showed negative 90-day outcomes. The company remains unprofitable with net income of $-112.7M over its last full fiscal year, though revenue surged 120.0% year-over-year. The timing of this sale—executed at a high point relative to current levels and consistent with his historical pattern of selling before subsequent declines—warrants close observation of the company's profitability trajectory and market momentum.

BEAM President sold 51,110 shares ($1.3M) on 2024-11-06 at $26.36; stock now -40.0% from 52-week high. Prior trades well-timed.

Ciaramella Giuseppe, President, disposed of 51,110 shares (31.9% of pre-transaction holdings) at $26.36, reducing his position from 160,260 to 109,150 shares. His cross-ticker track record shows a 100.00% well-timed rate at the 90-day mark across prior sells, with an average 90d return of -43.7%, and his two prior measured sales at BEAM in July 2023 were similarly well-timed, posting 90-day returns of -44.7% and -42.7%. The current stock price of $27.06 sits -40.0% below the 52-week high of $45.07, indicating significant downside has already occurred since the transaction. The company reported revenue of $14,269,000.00 in its latest quarter with a net loss of $-96,668,000.00 and remains unprofitable on a full-year basis, though annual revenue growth stands at +520.0%. The pattern of consistent well-timed exits at this ticker, paired with deteriorating financial returns (large quarterly losses despite revenue growth), aligns with the observed post-transaction decline.

Beam Therapeutics President sold 51,110 shares at $26.27; stock down 40.8% from 52-week high; insider's prior BEAM sales preceded 90-day declines of 44.7% and 42.7%.

Ciaramella Giuseppe, President of Beam Therapeutics, sold 51,110 shares (24.2% of his pre-transaction holdings) on 2024-10-14 at $26.27 per share, reducing his position from 211,370 to 160,260 shares. The stock is currently trading at $26.69, down 40.8% from its 52-week high of $45.07, and the company remains unprofitable with net income of $-91.1M against quarterly revenue of $11.8M. Notably, the President's two prior sales at Beam (2023-07-24 and 2023-07-21) were each followed by 90-day declines exceeding 42%, and his cross-ticker track record shows a 100.0% well-timed sell rate with an average 90-day return of -43.7%, suggesting a pattern of selling before downturns. Given the company's current depressed valuation relative to recent highs and the insider's demonstrated precision in prior BEAM divestitures, this sale warrants close attention to whether it signals anticipated headwinds.